# DEVELOPMENT OF A COMPOUND FOR THE TREATMENT OF COVID-19

> **NIH NIH N01** · ALIGOS THERAPEUTICS, INC. · 2023 · $8,469,477

## Abstract

To support the advanced development of a promising antiviral against a pathogen with pandemic potential. The research and development activities to be supported will allow the candidate therapeutic product to progress through the product development pathway, and include preclinical and IND enabling development activities, chemistry optimization/development, GMP manufacturing, and clinical safety and efficacy assessment.

## Key facts

- **NIH application ID:** 10933185
- **Project number:** 75N93023C00052-0-9999-1
- **Recipient organization:** ALIGOS THERAPEUTICS, INC.
- **Principal Investigator:** STANLEY WANG
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $8,469,477
- **Award type:** —
- **Project period:** 2023-09-22 → 2026-02-15

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10933185

## Citation

> US National Institutes of Health, RePORTER application 10933185, DEVELOPMENT OF A COMPOUND FOR THE TREATMENT OF COVID-19 (75N93023C00052-0-9999-1). Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/grant/nih/10933185. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*